A consolidated class action lawsuit against the EpiPen, an epinephrine autoinjector used to treat severe allergic reactions, is on trial – albeit on the basis of a shortened antitrust claim.
District Judge Daniel Crabtree in June threw back lawsuits under the Racketeer Influenced and Corrupt Organizations Act and some of the antitrust charges against Mylan Pharmaceuticals for selling the EpiPen, a pen-like device used to treat anaphylaxis, a potentially fatal disease that is caused by food allergies and insect bites.
